The Association for Molecular Pathology is pleased to present a two-part series:

**Who owns your genes?**

*Ensuring Patient Access to Molecular Testing*

Please join us for a virtual congressional briefing and follow-up discussion with experts to learn about current legislative efforts to allow companies to patent your DNA, which would *jeopardize medical research and health care*.

**Congressional Briefing**

Hosted in conjunction with ACLU, FORCE, and Invitae  
**Monday, October 17th**  
12-1 pm EST  
To RVSP for the Congressional Briefing Click [here](#)

Moderator:  
**Sarah Thibault-Sennett, Ph.D.**, Director of Public Policy & Advocacy, Association for Molecular Pathology

Speakers:  
**Sandra Park, J.D.**, Senior Staff Attorney, Women’s Rights Project, American Civil Liberties Union  
**Robert Nussbaum, M.D.**, Chief Medical Officer, Invitae Corporation  
**Lisa Schlager**, Vice President of Public Policy, FORCE: Facing Our Risk of Cancer Empowered  
**Karen Weck, M.D.**, Professor of Pathology and Clinical Genetics, University of North Carolina
Patient Advocate Conversation
Wednesday, October 26th
12-1 pm EST
To RVSP for the Patient Advocate Lunch and Learn Click here
If you cannot make the October 17th briefing, a recording will be circulated prior to the patient Advocate Lunch and Learn.

Host - Jill Murrell, PhD, Children’s Hospital of Pennsylvania
Speakers – Lisa Schlager, Vice President of Public Policy FORCE: Facing Our Risk of Cancer Empowered
Karen Weck, M.D., Professor of Pathology and Clinical Genetics, University of North Carolina.

The Association for Molecular Pathology (AMP) has been heavily involved in protecting patient genes from being patented. Prior to the unanimous 2013 Supreme Court decision that DNA is a product of nature and not patent eligible, at least 20% of the human genome was patented.

Unfortunately, legislation has been introduced to override that Supreme Court decision and many other judicial decisions – going back over a century – that protected fundamental things and ideas from exclusive patenting. The bill would once again allow patents on laws of nature, products of nature, and abstract ideas, in which genes and the association between genes and disease would be allowed to be patented.

AMP invites our valued patient advocacy partners to join us for a discussion of the Section 101, patient experiences with molecular diagnostic testing before and after the 2013 Supreme Court decision, and opportunities for AMP to work with the patient community to ensure continued access to molecular testing while legislation threatens it.

Please feel free to contact Samantha Pettersen at spettersen@amp.org with any questions.

You are receiving this invitation as part of the patient-engagement activities of the Association for Molecular Pathology, a professional association with members that provide molecular diagnostic testing for cancer, inherited disorders, and infectious diseases. We invite you to please reach out to us with any questions regarding molecular testing or suggestions as to how we can better support your patient community. We look forward to partnering with you in the future to ensure that all patients receive appropriate molecular testing!